{"entity":{"id":"nct03394365","kind":"trial","name":"A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failu","aka":["ALLELE"],"tldr":"A phase 3 trial of Tabelecleucel run by Pierre Fabre Medicament, now recruiting.","summary":"A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy is a phase 3 interventional study registered as NCT03394365 by Pierre Fabre Medicament, with 115 participants planned, started 2017-12-29. Conditions listed: Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03394365","url":"https://clinicaltrials.gov/study/NCT03394365"}],"tags":["ctgov-ingest"],"related":[],"cancers":["post-transplant-lymphoproliferative-disorder"],"sections":[],"technologies":["virus-specific-t-cells"],"targets":[],"drugs":["tabelecleucel"],"companies":["pierre-fabre"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03394365","phase":"3","setting":"Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy","sponsor":"Pierre Fabre Medicament","started":"2017-12-29","startedType":"actual","enrolled":115,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03394365/","neighbours":{"cancer":[{"id":"post-transplant-lymphoproliferative-disorder","kind":"cancer","name":"Post-transplant lymphoproliferative disorder (PTLD)","route":"/cancers/post-transplant-lymphoproliferative-disorder/"}],"technology":[{"id":"virus-specific-t-cells","kind":"technology","name":"Virus-specific T cells","route":"/technologies/virus-specific-t-cells/"}],"drug":[{"id":"tabelecleucel","kind":"drug","name":"Tabelecleucel","route":"/drugs/tabelecleucel/"}],"company":[{"id":"pierre-fabre","kind":"company","name":"Pierre Fabre","route":"/companies/pierre-fabre/"}]}}